AstraZeneca, Daiichi eye first-line breast cancer market after Enhertu's early Phase 3 win

AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of progression or death compared with the standard of care for first-line HER2-positive metastatic breast cancer, the companies said Monday. The finding could ...